Pulse Biosciences (NASDAQ:PLSE) Upgraded by StockNews.com to “Sell”

StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE) to a sell rating in a research report report published on Thursday morning.

Pulse Biosciences Stock Up 10.4 %

NASDAQ:PLSE opened at $11.01 on Thursday. Pulse Biosciences has a 12 month low of $3.78 and a 12 month high of $14.96. The firm’s 50 day moving average is $9.98 and its 200 day moving average is $9.54.

Pulse Biosciences (NASDAQ:PLSE) last issued its earnings results on Tuesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter.

Insiders Place Their Bets

In other Pulse Biosciences news, CEO Burke Thomas Barrett purchased 10,000 shares of the stock in a transaction dated Monday, May 20th. The shares were bought at an average price of $8.56 per share, with a total value of $85,600.00. Following the completion of the transaction, the chief executive officer now directly owns 10,000 shares in the company, valued at approximately $85,600. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 71.50% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

Several hedge funds have recently made changes to their positions in PLSE. Vanguard Group Inc. boosted its stake in Pulse Biosciences by 28.8% in the 1st quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock worth $7,379,000 after purchasing an additional 189,227 shares during the period. Griffin Asset Management Inc. increased its holdings in shares of Pulse Biosciences by 15.7% in the first quarter. Griffin Asset Management Inc. now owns 300,320 shares of the company’s stock worth $2,616,000 after purchasing an additional 40,700 shares during the period. PNC Financial Services Group Inc. purchased a new stake in shares of Pulse Biosciences in the fourth quarter worth $242,000. Cetera Advisors LLC bought a new stake in Pulse Biosciences during the first quarter valued at $109,000. Finally, Inspire Investing LLC grew its position in Pulse Biosciences by 32.1% during the first quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock worth $360,000 after buying an additional 10,039 shares in the last quarter. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.